Mid Diagnosed 2026-10-12 15:13:48 KST
B
BMY AI Stock Diagnostic Report
Bristol down as Street reacts to admilparant results in IPF Bristol-Myers Squibb's shares fell about 3% as the market reacted negatively to the Phase 3 results of its idiopathic pulmonary fibrosis drug, admilparant.
View Source Article ↗ AI CATALYST SCORE 45 / 100 Score computed by Sentinel V12
REFERENCE PRICE Not measured Reference entry price at analysis time
AI REFERENCE SCORE A reference score computed by the analysis engine from news and filings.
Report Info
Tier Mid
Diagnosed At 2026-10-12 15:13:48
Content Review Reviewed
Company Facts
Next Ex-Dividend Date Collecting
Next Earnings Date Collecting
Latest SEC Filing No recent notable filing Data Composition Shows Sentinel V12's AI analysis, plus (for S-Class) Python Engine technical indicators and stored OHLC data.
+ ANALYSIS HISTORY
BMY Analysis History (Last 30 Days)